Actimis Pharmaceuticals

Actimis Pharmaceuticals, Inc. is a start-up biopharmaceutical company dedicated to developing small molecule therapeutics aimed at treating respiratory and inflammatory disorders. Founded by Dr. Kevin Bacon as a spin-off from Bayer Healthcare AG's research portfolio, Actimis focuses on conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease, and rheumatoid arthritis. The company aims to provide effective treatment options for these diseases, enabling physicians to improve patient outcomes. Actimis has secured venture financing from a syndicate led by Sanderling Ventures and Mitsui & Co Venture Partners, facilitating its ambitious development initiatives.